Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD

Key Points

• Algert Global reduced its iRadimed stake by 17.1% in the second quarter, selling 15,062 shares and retaining 72,994 shares. Institutional investors collectively own 92.34% of the company.
• iRadimed exceeded quarterly expectations, reporting $0.46 in EPS on $20.47 million in revenue, while issuing fiscal 2026 EPS guidance of $2.09–$2.24. Analysts maintain a “Moderate Buy” consensus with a $120 price target.
• The company declared a quarterly dividend of $0.20 per share, equivalent to $0.80 annually and a 0.9% yield. CEO Roger E. Susi also sold 2,500 shares under a pre-arranged trading plan.

Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ:IRMD - Free Report) by 17.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global LLC owned 0.57% of iRadimed worth $6,975,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Ranger Investment Management L.P. bought a new stake in iRadimed during the second quarter worth about $9,398,000. Globeflex Capital L P bought a new position in shares of iRadimed during the second quarter valued at approximately $1,486,000. Quantbot Technologies LP purchased a new position in shares of iRadimed during the second quarter valued at approximately $521,000. Virtus Advisers LLC purchased a new position in shares of iRadimed during the second quarter valued at approximately $179,000. Finally, BlackRock Inc. bought a new stake in shares of iRadimed in the 2nd quarter worth approximately $92,485,000. Institutional investors own 92.34% of the company's stock.

Insider Activity at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the firm's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares of the company's stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 34.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IRMD. Wall Street Zen cut shares of iRadimed from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings downgraded shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Stock Down 0.5%

IRMD opened at $87.47 on Thursday. The company has a market capitalization of $1.12 billion, a PE ratio of 48.87 and a beta of 0.90. The firm has a 50-day simple moving average of $93.16 and a two-hundred day simple moving average of $94.29. iRadimed Corporation has a 52 week low of $67.84 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The company had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's dividend payout ratio is presently 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.